Scholl Hendrik Peter Sells Shares of Belite Bio, Inc $BLTE
Key Points
- Scholl Hendrik Peter sold 10,000 shares of Belite Bio, Inc ($BLTE) worth $1.41 million.
- $BLTE last traded around $148.34.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Scholl Hendrik Peter, Chief Medical Officer at Belite Bio, Inc ($BLTE), sold 10,000 shares at an average price of $140.57, for a total transaction of $1.41 million. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Belite Bio, Inc Stock Down 2.2%
Shares of Belite Bio, Inc ($BLTE) traded around $148.34 on Thursday, down 2.2% for the day.
Belite Bio, Inc Earnings
Analysts Set New Price Targets
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Get Belite Bio, Inc alerts
New 13F filings, insider trades, and analyst moves on $BLTE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.